Multivariate analysis for relapse.
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Proportional hazards model | ||||||
| Eosino, 1000/µl | 0.970 | 0.940–1.000 | 0.049 | 0.946 | 0.907–0.987 | 0.011 |
| IgE, 100 IU/ml | 1.016 | 1.002–1.031 | 0.029 | 1.025 | 1.011–1.039 | < 0.001 |
| ANCA | ||||||
| Negative | Ref. | Ref. | ||||
| Positive | 1.633 | 1.011–2.637 | 0.045 | 1.391 | 0.755–2.565 | 0.290 |
| IS use | ||||||
| None | Ref. | Ref. | ||||
| CYC for induction | 1.746 | 1.023–2.981 | 0.041 | 1.285 | 0.673–2.452 | 0.447 |
| CYC for induction + AZA for maintenance | 0.413 | 0.163–1.045 | 0.062 | 0.261 | 0.079–0.870 | 0.029 |
| Competing risk model | ||||||
| Age | 0.984 | 0.966–1.002 | 0.087 | 0.984 | 0.967–1.002 | 0.076 |
| Serum creatinine | 0.462 | 0.189–1.126 | 0.089 | 0.626 | 0.291–1.348 | 0.232 |
| Female | Ref. | Ref. | ||||
| Male | 0.578 | 0.311–1.076 | 0.084 | 0.642 | 0.348–1.183 | 0.155 |
Eosino: eosinophil count; IgE: immunoglobulin E; ANCA: antineutrophil cytoplasmic antibodies; IS: immunosuppressant; CYC: cyclophosphamide; AZA: azathioprine.